

**Supplemental Table 1: Correlation between participant characteristics and FMD at baseline assessment**

	Correlation with FMD	
	Spearman r	P
<b>AAA AP diameter (mm)</b>	-.28	.0003
<b>Age (years)</b>	.06	.49
<b>Gender</b>	-.03	.72
<b>Height (m)</b>	-.06	.45
<b>Weight (kg)</b>	.01	.94
<b>BMI</b>	.02	.76
<b>Systolic BP (mmHg)</b>	-.001	.99
<b>Diastolic BP (mmHg)</b>	-.01	.23
<b>Total Cholesterol (mmol/L)</b>	-.02	.85
<b>HDL (mmol/L)</b>	-.01	.88
<b>Calculated LDL (mmol/L)</b>	-.1	.27
<b>Triglycerides (mmol/L)</b>	.08	.33
<b>Creatinine (umol/L)</b>	-.05	.58
<b>CRP (mg/L)</b>	-.06	.49
<b>History of smoking</b>		
Never Smoked	.01	.94
Ex-smoker	.05	.50
Current smoker	-.07	.37
<b>History of diabetes</b>	-.004	.96
<b>HbA1c (mmol/mol)</b>	-.06	.52
<b>History of coronary heart disease</b>	-.02	.85
<b>History of peripheral vascular disease</b>	.04	.80
<b>History of cerebral vascular disease</b>	.03	.72
<b>History of chronic respiratory disease</b>	.09	.26
<b>Family history of AAA</b>	-.1	.24
<b>Regular medications</b>		
Aspirin	-.07	.42
Statins	.09	.28
Beta-Blockers	-.05	.51
ACEI/A <sub>2</sub> RA	.07	.40
Anti-platelets	-.01	.93
Oral anticoagulant	.01	.89